Human umbilical cord cells: a new cell source for cardiovascular tissue engineering
Section snippets
Cell isolation and cultivation
Human umbilical cord and saphenous vein sections (2 to 3 cm in length) were washed with Dulbecco’s phosphate buffered saline (Gibco, Rockville, MD) and minced into 1-mm pieces, which 100 × 15-mm Petri dishes (Gibco). Tissue sections were cultured with Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (HyClone) and Gentamycin (Gibco). Medium was replaced at 24 and 72 hours and every 6 days thereafter. Daily progress was monitored by phase-contrast
Histology and immunophenotyping of UCC
Hematoxylin and eosin and Trichrome-masson staining of fixed cells showed elongated cells with fibroblast-like morphology as well as deposition of extracellular matrix throughout the cell culture. Immunohistochemistry revealed intracellular expression of ASMA and vimentin, along with formation of collagen I and III (Fig 1). Cultured UCC did not stain positive for the endothelial cell marker CD 31.
Flow cytometry
Results of the FACS analysis of UCC are shown in Figure 2. The UCC characterization by flow
Comment
Living tissue-engineered constructs appear to be an attractive new concept for cardiovascular surgery, especially for the repair of congenital cardiac defects. The creation of viable substitutes with the ability to regenerate, remodel, and grow would have substantial advantages over currently available materials and prostheses.
In the present study, we evaluated the feasibility of using an alternative autologous cell source—namely, human UCC—for tissue engineering of cardiovascular constructs.
Acknowledgements
The authors thank Manfred Welti, Laboratory for Tissue Engineering and Cell Transplantation, University Hospital Zurich, for his valuable work on cell culture, and Klaus Marquard, Department of Surgical Research, University Hospital Zurich, for providing the scanning electron microscopy pictures. We further thank Dr. Jeroen F Visjager, Swiss Institute of Technology, Zurich, for performing the biomechanical testing. Finally, we are grateful to Annegret Bittermann and Oliver Hoechli, Electron
References (22)
- et al.
Separation of neointima from Dacron graft causing obstruction
J Thorac Cardiovasc Surg
(1981) - et al.
Evidence for rejection of homograft cardiac valves in infants
J Thorac Cardiovasc Surg
(1998) - et al.
Long-term function of cryopreserved aortic homografts
J Thorac Cardiovasc Surg
(1993) - et al.
Patch augmentation of the pulmonary artery with bioabsorbable polymers and autologous cell seeding
J Thorac Cardiovasc Surg
(2000) - et al.
Study on myofibroblast differentiation in the stromal cells of Wharton’s jellyexpression and localization of alpha-smooth muscle actin
Early Hum Dev
(1998) - et al.
Tissue engineered valve constructs in the pulmonary circulation
J Thorac Cardiovasc Surg
(2000) - et al.
Tissue engineering of autologous aorta using a new biodegradable polymer
Ann Thorac Surg
(1999) Uses of homograft conduits for right ventricle to pulmonary connections in the neonatal period
Semin Thorac Cardiovasc Surg
(1995)- et al.
Late pericarditis secondary to pericardial patch implantation 25 years prior
Eur J Cardio-thorac Surg
(2001) - et al.
Growth of fresh-frozen pulmonary allograft conduit in growing lambs
Circulation
(1989)
Pathological considerations in cryopreserved allograft heart valves
J Heart Valve Dis
Cited by (120)
Heart valve tissue engineering
2020, Principles of Tissue EngineeringNanofiber composites in cardiac tissue engineering
2017, Nanofiber Composites for Biomedical ApplicationsTherapeutic potentials of umbilical cord–derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation
2017, CytotherapyCitation Excerpt :However, ITBLs are frequently resistant to the traditional therapy, and retransplantation is the only option in up to 50% of the patients [9,10]. Mesenchymal stromal cells (MSCs) are characterized by the immunosuppressive and regenerative properties that make MSCs very attractive in treating immunologic diseases, including transplant rejection [11–19], and organ/tissue ischemic injury [20–27]. Considering the damage of peribiliary vascular plexus of biliary duct and immunologic injury are the main mechanisms of ITBLs, we hypothesized that MSCs transfusions may thus constitute a new therapeutic option for patients with ITBLs.
6.15 Tissue engineering of heart valves
2017, Comprehensive Biomaterials II7.27 Cardiac valves: Biologic and synthetic
2017, Comprehensive Biomaterials II